BioSpace News Archive

Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today presents clinical data on its Phase 1 AMELI-01 clinical trial (evaluating UCART123) that were unveiled in an oral presentation at the 64th American Society of Hematology (ASH) annual meeting.

Evofem Biosciences, Inc., announced a 1-for-125 reverse stock split of the Company’s common stock, which was approved by the stockholders of the Company at the special meeting of stockholders held on March 15, 2023.

AIDS Healthcare Foundation supports an appeal by Médecins Sans Frontières urging Abbott Laboratories and Becton Dickinson to continue production of equipment and consumables for point-of-care CD4 machines. Both companies have announced that they will phase out the production of cartridges and devices over the coming years, including Abbott’s Pima CD4 analyzers, which AHF widely uses around the world.

Sirnaomics Ltd. has received approval of an HK$8 million subsidy from the Hong Kong Science and Technology Parks Corporation, which will be used to accelerate research and development of its leading RNAi drug candidate, STP122G, a GalNAc-based innovative anticoagulant therapeutic.

Precision Optics Corporation, Inc. (NASDAQ: POCI) today announced Dr. Joe Forkey, CEO, will participate in a fireside chat and host one-on-one meetings with investors at the Lytham Partners Spring 2023 Investor Conference, taking place virtually on May 18, 2023.

Shuttle Pharmaceuticals Holdings, Inc. announced today that its Chief Executive Officer, Anatoly Dritschilo , M.D., will be participating in a Webcast and Panel Presentation at the Lytham Partners Spring 2023 Investor Conference (the “Conference”) on Thursday, May 18, 2023.

Deepcell, a pioneer in artificial intelligence (AI)-powered single cell analysis to fuel deep biological discoveries, today announced the launch of the REM-I Platform, a high-dimensional cell morphology analysis and sorting platform which comprises the REM-I benchtop instrument, Human Foundation Model, and Axon data suite.

Abcam plc, a global leader in the supply of life science research tools, announces the voting results from the Annual General Meeting.

AmbioPharm, a worldwide leader in peptide API CDMO services, continues growth to meet capacity demands for late phase and commercial peptide production while increasing our sustainability efforts.

Flavocure Biotech, Inc. (“Flavocure”), today announced that it has received clearance of its Investigational New Drug (IND) application from the U.S. Food and Drug Administration (FDA) to initiate a Phase I, first-in-human clinical study of Caflanone (FBL-03G) for the treatment of pancreatic cancer.